Resistance to tyrosine kinase inhibitors
The RAS ‐related GTP ase RHOB confers resistance to EGFR ‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT ‐dependent mechanism
... EGFR-tyrosine kinase inhibitors (EGFR-TKI) are widely used to treat metastatic NSCLC in patients bearing EGFR-activating mutations, which are most commonly the L858R point mutation and the ...
14
The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism
... EGFR-tyrosine kinase inhibitors (EGFR-TKI) are widely used to treat metastatic NSCLC in patients bearing EGFR-activating mutations, which are most commonly the L858R point mutation and the ...
14
Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma
... 8. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. ...
46
en fr Mechanisms of resistance to tyrosine kinase inhibitors on the model of chronic myeloid leukemia Mécanismes de résistance aux inhibiteurs de tyrosine kinase sur le modèle de leucémie myéloïde chronique
... autocrines et paracrines de GM-CSF ou IL3 et constituerait un des mécanismes de résistance aux inhibiteurs de tyrosine kinase 94,95 . Des voies de régulation négatives interviennent sur la transduction du ...
111
Implicating the mechanisms of ADP-ribosylation factor activation in the resistance of invasive breast cancer cells to EGFR tyrosine kinase inhibitors
... modifies to the actin cytoskeleton (D'Souza-Schorey, Li et ...unique to other small GTPases in that these proteins undergo two conformational changes in response to its GTP ...residues to ...
270
Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
... thought to be involved in ovarian neoplasms and small-cell lung cancer ...several inhibitors of TK have been developed for the treatment of cancer and other ...of resistance by most if not all ...
13
Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.
... confer resistance to current available agents, especially the fre- quently occurring T790M ...able to inhibit T790M and EGFR mRNA, to reduce EGFR protein expression, as well as to ...
7
en fr Identification and vectorization of combination of drugs for the treatment of lung tumors resistant to EGFR tyrosine kinase inhibitors Identification et vectorisation de combinaisons de traitements pour la thérapie des tumeurs pulmonaires résistantes aux inhibiteurs de tyrosine kinase de l'EGFR
... EGFR-TKIs. Resistance to TKI has been associated with the presence of a KRAS mutation, 27 most likely through the direct activation of downstream Ras effector pathways MEK/ERK1/2 and ...leads to ...
251
Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma
... response to current treatment highlight a great need for better rational ...mimetic, to kill MCL ...sensitive to ABT-199 (LD 50 < 10 nM). Mcl-1 and Bcl-x L both confer resistance to ...
11
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group
... with resistance was found. 28 The ongoing LAST trial, designed to evaluate imatinib, dasati- nib, nilotinib, or bosutinib discontinuation, excludes patients with a history of resistance but not ...
8
Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
... acquired resistance to gefitinib in TNBC cell lines ...G1 to S phase ...led to increased sensitivity to erlotinib in EGFR- expressing TNBC cell line ...known to induce the ...
21
The role of RICTOR downstream of receptor tyrosine kinase in cancers
... pharmalogical inhibitors or knockdown of mTORC1/RAPTOR and mTORC2/RICTOR, attenu- ated migration and invasion of CRC cells, induced a mesenchymal–epithelial transition and enhanced che- mosensitivity of CRC cells ...
11
Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
... close to the healthy ...IMA resistance. Several possible mechanisms of resistance have been demonstrated in ...BCR‐ABL kinase domain (KD) mutations remains the most documented one in vivo, ...
11
Bruton's Tyrosine Kinase (BTK) and Vav1 Contribute to Dectin1-Dependent Phagocytosis of Candida albicans in Macrophages
... Figure 8. Phenotypic analysis of BTK- and Vav1-deficient macrophages and mice. (A): Peritoneal macrophages or bone marrow-derived macrophages (BMDM) from wild type, dectin12/2, btk2/2 or vav12/2 mice were incubated with ...
16
Leucémie myéloïde chronique : modalités d'arrêt du traitement par inhibiteur de tyrosine kinase (ITK)
... de tyrosine kinase a transformé la prise en charge de cette maladie et a permis aux patients d’avoir une espérance de vie similaire à la population ...
91
Resistance to the proteasome inhibitors: Lessons from multiple myeloma and mantle cell lymphoma
... capacity to synthesize and secrete immunoglobulins, MM cells exhibit an expanded ER network and an increased ability to cope with unfolded or misfolded proteins that accumulate in the ...referred to ...
32
Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
... subjected to lysis in NuPAGE LDS Sample ...cording to the manufacturer ’s ...transferred to nitrocellulose membranes (70 min, ...normalized to their corresponding loading ...
35
Bis-imide granulatimide analogues as potent Checkpoint 1 kinase inhibitors.
... L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignemen[r] ...
8
Les récepteurs à domaine discoïdine : une variété de récepteurs à activité tyrosine kinase se liant aux collagènes
... entre les deux précédents et un domaine intracellu- laire porteur de l’activité tyrosine kinase [3] . DDR1 et DDR2 sont détectés sous la forme de protéines glycosylées de 125 et 130 kDa, respectivement. Le ...
3
Les inhibiteurs de la tyrosine kinase dans la leucmie mylode chronique, un modle russi de thrapie cible
... La protéine BCR est constituée de plusieurs domaines. Dans la partie N-terminale, le domaine 1B constitue une région importante puisqu’il permet la dimérisation de la protéine BCR-ABL conduisant à l’ouverture de ...
156